dc.creator | Ma, Cuiqing | |
dc.creator | Su, Shan | |
dc.creator | Wang, Jiachao | |
dc.creator | Wei, Lin | |
dc.creator | Du, Lanying | |
dc.creator | Jiang, Shibo | |
dc.date.accessioned | 2020-07-23T16:42:03Z | |
dc.date.accessioned | 2022-09-23T18:48:37Z | |
dc.date.available | 2020-07-23T16:42:03Z | |
dc.date.available | 2022-09-23T18:48:37Z | |
dc.date.created | 2020-07-23T16:42:03Z | |
dc.identifier | 1286-4579 | |
dc.identifier | https://doi.org/10.1016/j.micinf.2020.05.004 | |
dc.identifier | http://hdl.handle.net/20.500.12010/11042 | |
dc.identifier | https://doi.org/10.1016/j.micinf.2020.05.004 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3507793 | |
dc.description.abstract | The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has
posed serious threats to public health and economic stability worldwide, thus calling for development of
vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and
SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it
is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the
development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the
advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the
development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by
currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause
future epidemics or pandemics | |
dc.publisher | Science Direct | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.source | reponame:Expeditio Repositorio Institucional UJTL | |
dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | |
dc.subject | 2019-nCoV | |
dc.subject | SARS-CoV-2 | |
dc.subject | HCoV-19 | |
dc.subject | SARS-CoV | |
dc.subject | Vaccine | |
dc.subject | Cross-protection | |
dc.title | From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development | |